Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 15c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q3 EPS of $0.06, $0.15 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $99.2 million versus the consensus estimate of $86.99 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• TD Cowen 'Summarizing Recent Expert Conversations' on McDonald's (MCD)
• Mistral AI in talks to raise funds at €20b valuation - Bloomberg